Back to Search
Start Over
Metabolic agents in the management of diabetic coronary patients: a new era.
- Source :
-
International journal of cardiology [Int J Cardiol] 2008 Jun 23; Vol. 127 (1), pp. 124-5. Date of Electronic Publication: 2008 Jan 15. - Publication Year :
- 2008
-
Abstract
- The modulation of cardiac metabolism with Trimetazidine is very important for the control of myocardial ischemia and for the preservation of left ventricular function. The optimization of cardiac metabolism should also include improvement of cardiac insulin resistance with insulin sensitizer agents and the optimization of Kreb's Cycle with essential amino acids. Regarding new drugs that may act inhibiting free fatty acid oxidation we have to underline that to date it is not clear whether Ranolazine has an effect on cardiac metabolism. We agree instead that metabolic agents like Dichloroacetate, Perhexiline and Etomoxir have an antiischemic effect, while their administration requires adjustment of dose and careful monitoring of side effects.
- Subjects :
- Acetanilides therapeutic use
Citric Acid Cycle
Dichloroacetic Acid therapeutic use
Enzyme Inhibitors therapeutic use
Epoxy Compounds therapeutic use
Humans
Insulin Resistance
Perhexiline therapeutic use
Piperazines therapeutic use
Ranolazine
Trimetazidine therapeutic use
Vasodilator Agents therapeutic use
Coronary Disease complications
Coronary Disease drug therapy
Diabetes Mellitus, Type 2 complications
Diabetic Angiopathies complications
Subjects
Details
- Language :
- English
- ISSN :
- 1874-1754
- Volume :
- 127
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- International journal of cardiology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 18199501
- Full Text :
- https://doi.org/10.1016/j.ijcard.2007.10.042